HAVANA, Cuba, Oct 8 (ACN) Odalis Maria de la Guardia Peña, a second degree specialist in immunology, considered promising the preliminary results obtained at the conclusion of the first phase of the clinical trial to use stem cells in patients who suffered lung lesions due to COVID-19.
The study, carried out since May at the Institute of Hematology and Immunology (IHI by its Spanish acronym), seeks to eliminate or reduce interstitial inflammatory or fibrotic lesions in the lungs after the infection, according to Granma newspaper.
De la Guardia, who is also Master in Infectious Diseases and Head of External Services at the IHI, explains the research will have a great impact "if, as we hope, stem cell therapy gives positive results in these patients with pulmonary alterations POS-COVID-19".
If the treatment is effective, it would be generalized to the entire country and would improve the quality of life and respiratory capacity of these patients, she added.
Although the affectations caused by SARS-COV-2 are diverse (cardiovascular, in the kidney, in the brain, the vascular system, in distal or lower limbs, and others); the "target" organ in the case of SARS-COV-19 is the lung, in which patients can present affectations both during the disease and once they have recovered, which is studied at an international level, the expert explained.
We searched for those who presented a more torpid evolution, of more than 20 days in a hospital institution, with the need of the use of oxygen or assisted ventilation, in a serious or critical state, or with the need of the use of some aerosol as treatment, the doctor continued.
The study is still in progress, and although the first part has already concluded, there is still time to make the final evaluation of the patient, De la Guardia concluded.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio